Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Intensive Rehabilitation

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-11-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: paininjuryopioidspinaltraumatic
  Phrases that lowered it: mgdosepatientopen labelequivalent
• Sponsor's past termination rate: 32.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Blinding: single (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 29.3% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 78.4% (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 34 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports before start: 173490 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury NCT04379011 · started 2021 · scored riskier than 45% of active trials completed
• Relieving Acute Pain (RAP) Study: A Pilot Study NCT03426137 · started 2018 · scored riskier than 96% of active trials terminated
• Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury NCT04057456 · started 2023 · scored riskier than 44% of active trials completed
• NVG-291 in Spinal Cord Injury Subjects NCT05965700 · started 2023 · scored riskier than 79% of active trials completed
• Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training NCT03979742 · started 2022 · scored riskier than 73% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.